Since the HGF-MET axis is frequently dysregulated in many types of cancer and MET dysregulation is associated with an increased propensity for metastatic disease and poor overall prognosis [32], HGF/MET inhibition has emerged as a target for anticancer therapies. Here, HGF is linked to metastatic neoplasm.